Enter assignee name

% Expired Patents = 83.3

EPO Patents = 1

Forward Citations = 16

Loading Chart...

15 inventors (with patents filed for the assignee):

Jean-Francois Pons (4 out of 5 patents)

Manuel A Navia (3 out of 19 patents)

Jeffrey O Saunders (3 out of 68 patents)

4. Andrew Napper (3 out of 3 patents)

5. Peter DiStefano (3 out of 3 patents)

6. Rory A Curtis (3 out of 3 patents)

7. L Julie Huber (3 out of 3 patents)

8. Jonathan M Solomon (3 out of 4 patents)

9. Russell Thomas (2 out of 17 patents)

10. Jay R Luly (2 out of 61 patents)

11. Thomas Stephen Coulter (1 out of 13 patents)

12. Jeffrey Hixon (1 out of 1 patent)

13. Paul Mortenson (1 out of 1 patent)

14. Thomas E McDonagh (1 out of 5 patents)

15. Russell J Thomas (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 8486990 - SirT inhibitors that bind to NAD (2013-07-16),

2. 7897765 - Therapeutic compounds and uses thereof (2011-03-01),

3. 7829589 - Sulfonamide compounds and uses thereof (2010-11-09),

4. 7771961 - Cytochrome c acetylation (2010-08-10),

5. 7575883 - Cytochrome c acetylation (2009-08-18),

6. 7504506 - Therapeutic compounds and uses thereof (2009-03-17),

Elixir Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for aging-associated diseases. Their research and development efforts are centered around utilizing small molecule drugs to target key pathways involved in aging and age-related illnesses. With a commitment to improving the health and quality of life for aging populations, Elixir Pharmaceuticals aims to bring groundbreaking treatments to market that address unmet medical needs in the aging space.

Profile summary based on public USPTO records.